CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 77.3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

VirBiotechnology live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

VirBiotechnology news

Laatste marktnieuws

Toon meer
Ghko B 2025 Jun 15, 16:00

Trump Crypto Coin News: How much is Trump Coin worth today?

Cryptocurrencies
Ghko B 2025 Jun 15, 16:00

Crypto market news today: Japan’s Metaplanet purchases 1,112 BTC

Cryptocurrencies
Darius Anucauskas 2025 Jun 15, 16:00

Morning Note: Geopolitical Risks Persist; Major Central Bank & Economic Data Week Ahead

Morning Note Forex
Tommy Yap 2025 Jun 15, 16:00

Morning Note: Gold Nears High on Mideast Tensions; Franc Soars; ECB Update

Morning Note Commodities Forex
Tommy Yap 2025 Jun 14, 21:00

Week Ahead: Interest Rate Decision from BoJ, Fed, SNB and BoE on Spotlight

Forex Indices
Frances Wang 2025 Jun 12, 16:00

Stellar (XLM) Price Analysis: Where could XLM go in the upcoming days?

Stocks
Frances Wang 2025 Jun 12, 16:00

Crypto News Today: Bitcoin Price Down 1.85% as US PPI Rises

Cryptocurrencies
Ghko B 2025 Jun 12, 16:00

Dogecoin Price Prediction: Could Dogecoin Price Surge to $0.95?

Cryptocurrencies

Info

Spread

0.05

Spread (%)

0.9579 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Dinsdag

13:31 - 19:59

Maandag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

721602304

Uitstaande aandelen

138238000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-4.23

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten

latest_education_articles

Toon meer
Trustpilot